Aung Pyae Phyo

List of Publications by Year
in descending order

103 papers	12,540 citations	57758 44 h-index	37204 96 g-index
112 all docs	112 docs citations	112 times ranked	9433 citing authors

#	Article	IF	Citations
1	Artemisinin Resistance inPlasmodium falciparumMalaria. New England Journal of Medicine, 2009, 361, 455-467.	27.0	2,873
2	Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
3	Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet, The, 2012, 379, 1960-1966.	13.7	768
4	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515
5	Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatmentsâ€"a WWARN individual patient data meta-analysis. BMC Medicine, 2019, 17, 1.	5.5	465
6	Malaria. Lancet, The, 2018, 391, 1608-1621.	13.7	374
7	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	4.0	368
8	A Major Genome Region Underlying Artemisinin Resistance in Malaria. Science, 2012, 336, 79-82.	12.6	334
9	Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 240-245.	7.1	242
10	Genomic epidemiology of artemisinin resistant malaria. ELife, 2016, 5, .	6.0	242
11	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
12	Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine, 2014, 371, 403-410.	27.0	197
13	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
14	Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thaiâ€"Myanmar Border (2003â€"2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	5.8	178
15	Drugs in Development for Malaria. Drugs, 2018, 78, 861-879.	10.9	154
16	Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thaiâ€"Myanmar Border, 1999â€"2011: An Observational Study. PLoS Medicine, 2013, 10, e1001398.	8.4	150
17	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147
18	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet, The, 2018, 391, 1916-1926.	13.7	131

#	Article	IF	Citations
19	Population genetic correlates of declining transmission in a human pathogen. Molecular Ecology, 2013, 22, 273-285.	3.9	129
20	Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biology, 2017, 18, 78.	8.8	120
21	Combating multidrugâ€resistant Plasmodium falciparum malaria. FEBS Journal, 2017, 284, 2569-2578.	4.7	114
22	Exploring the Contribution of Candidate Genes to Artemisinin Resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2010, 54, 2886-2892.	3.2	110
23	Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Medicine, 2017, 14, e1002224.	8.4	106
24	Quantifying connectivity between local Plasmodium falciparum malaria parasite populations using identity by descent. PLoS Genetics, 2017, 13, e1007065.	3.5	98
25	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
26	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	9.1	94
27	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine, 2016, 375, 1152-1160.	27.0	89
28	Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1997-2007.	3.2	88
29	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2017, 34, 131-144.	8.9	87
30	Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood. Malaria Journal, 2009, 8, 115.	2.3	86
31	The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. PLoS Medicine, 2013, 10, e1001564.	8.4	86
32	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	9.1	85
33	Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial. PLoS ONE, 2011, 6, e14501.	2.5	74
34	Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial. Clinical Infectious Diseases, 2011, 53, 977-984.	5.8	71
35	Effect of Early Detection and Treatment on Malaria Related Maternal Mortality on the North-Western Border of Thailand 1986â€“2010. PLoS ONE, 2012, 7, e40244.	2.5	71
36	An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia. PLoS ONE, 2010, 5, e11880.	2.5	69

#	Article	IF	Citations
37	Pyronaridineâ€“Artesunate versus Mefloquine plus Artesunate for Malaria. New England Journal of Medicine, 2012, 366, 1298-1309.	27.0	68
38	Randomized, Double-Blind, Placebo-Controlled Trial of Monthly versus Bimonthly Dihydroartemisinin-Piperaquine Chemoprevention in Adults at High Risk of Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1571-1577.	3.2	62
39	Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. British Journal of Clinical Pharmacology, 2012, 73, 467-477.	2.4	60
40	Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 5500-5506.	3.2	59
41	Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malaria Journal, 2011, 10, 113.	2.3	53
42	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	6.0	53
43	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2018, 67, 1543-1549.	5.8	52
44	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
45	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50
46	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2019, 68, 1311-1319.	5.8	49
47	Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria. Clinical Infectious Diseases, 2013, 56, e48-e58.	5.8	48
48	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
49	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	12.8	46
50	Pharmacokinetics of Amodiaquine and Desethylamodiaquine in Pregnant and Postpartum Women with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 4338-4342.	3.2	45
51	Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. Journal of Infectious Diseases, 2013, 208, 801-812.	4.0	43
52	The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background. Nature Communications, 2018, 9, 5158.	12.8	41
53	Artemisinin-ResistantPlasmodium falciparumK13 Mutant Alleles, Thailandâ€“Myanmar Border. Emerging Infectious Diseases, 2016, 22, 1503-1505.	4.3	37
54	Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Medicine, 2015, 12, e1001823.	8.4	36

#	Article	IF	Citations
55	Pooled Sequencing and Rare Variant Association Tests for Identifying the Determinants of Emerging Drug Resistance in Malaria Parasites. Molecular Biology and Evolution, 2015, 32, 1080-1090.	8.9	34
56	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
57	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
58	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
59	Opposite malaria and pregnancy effect on oral bioavailability of artesunate â€“ a population pharmacokinetic evaluation. British Journal of Clinical Pharmacology, 2015, 80, 642-653.	2.4	29
60	Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malaria Journal, 2013, 12, 411.	2.3	28
61	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
62	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
63	Clinical impact of vivax malaria: A collection review. PLoS Medicine, 2022, 19, e1003890.	8.4	25
64	Challenges to replace ACT as first-line drug. Malaria Journal, 2017, 16, 296.	2.3	24
65	Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-8.	2.5	21
66	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
67	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. Antimicrobial Agents and Chemotherapy, 2021, 65, e0112121.	3.2	21
68	Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand. Malaria Journal, 2008, 7, 233.	2.3	20
69	Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. Malaria Journal, 2017, 16, 480.	2.3	20
70	Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. Journal of Infectious Diseases, 2019, 220, 100-104.	4.0	19
71	Plasmodium vivax Susceptibility to Ferroquine. Antimicrobial Agents and Chemotherapy, 2010, 54, 2228-2230.	3.2	17
72	Poor response to artesunate treatment in two patients with severe malaria on the Thaiâ€“Myanmar border. Malaria Journal, 2018, 17, 30.	2.3	16

#	Article	IF	Citations
73	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2020, 18, 138.	5.5	16
74	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16
75	Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study. Journal of Infectious Diseases, 2017, 216, 723-731.	4.0	15
76	Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax. Journal of Infectious Diseases, 2011, 203, 207-210.	4.0	14
77	Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. PLoS ONE, 2020, 15, e0235625.	2.5	14
78	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. AAPS Journal, 2017, 19, 1842-1854.	4.4	12
79	Plasmodium falciparum rosetting protects schizonts against artemisinin. EBioMedicine, 2021, 73, 103680.	6.1	12
80	Genetic Evaluation of the Performance of Malaria Parasite Clearance Rate Metrics. Journal of Infectious Diseases, 2013, 208, 346-350.	4.0	11
81	A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Medicine, 2021, 19, 132.	5.5	11
82	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 0, 6, 64.	1.8	11
83	The Presence of Leukocytes in Ex Vivo Assays Significantly Increases the 50-Percent Inhibitory Concentrations of Artesunate and Chloroquine against Plasmodium vivax and Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2011, 55, 1300-1304.	3.2	10
84	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2021, 65, e0130221.	3.2	10
85	The Artemisinin Resistance in Southeast Asia: An Imminent Global Threat to Malaria Elimination. , 0, , .		8
86	Malaria in the Post-Partum Period; a Prospective Cohort Study. PLoS ONE, 2013, 8, e57890.	2.5	7
87	The role of pointâ€ofâ€care tests in antibiotic stewardship for urinary tract infections in a resourceâ€limited setting on the Thailandâ€“Myanmar border. Tropical Medicine and International Health, 2015, 20, 1281-1289.	2.3	7
88	Reply to Meshnick and Hastings et al. Clinical Infectious Diseases, 2016, 63, 1528-1529.	5.8	7
89	Geographical distribution of Burkholderia pseudomallei in soil in Myanmar. PLoS Neglected Tropical Diseases, 2021, 15, e0009372.	3.0	7
90	Two fatal cases of melioidosis on the Thai-Myanmar border. F1000Research, 2014, 3, 4.	1.6	7

#	Article	IF	Citations
91	Triple artemisinin-based combination therapies for malaria: proceed with caution â€“ Authors' reply. Lancet, The, 2020, 396, 1976-1977.	13.7	6
92	Serological evidence indicates widespread distribution of rickettsioses in Myanmar. International Journal of Infectious Diseases, 2021, 103, 494-501.	3.3	5
93	Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
94	New malaria maps. Lancet, The, 2019, 394, 278-279.	13.7	4
95	Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 914-921.	1.8	4
96	Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?. Lancet Infectious Diseases, The, 2020, 20, 883-885.	9.1	2
97	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
98	Title is missing!. , 2020, 17, e1003393.		0
99	Title is missing!. , 2020, 17, e1003393.		0
100	Title is missing!. , 2020, 17, e1003393.		0
101	Title is missing!. , 2020, 17, e1003393.		0
102	Title is missing!. , 2020, 17, e1003393.		0
103	Case Report: A case report of multiple co-infections (melioidosis, paragonimiasis, Covid-19 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Research, 0, 7, 160.	1.8	0